Genprex gets Australian patent acceptance for Reqorsa+PD-L1; adds trial site

Genprex, Inc.

IP Australia issued Notice of Acceptance on Feb 5, 2026 for patent covering Reqorsa + PD-L1 antibodies in cancer.
Opened additional Acclaim-3 clinical trial site at University of Kentucky; plans more sites to expand enrollment.
Acclaim-3 Phase 2 expansion targets ~50 patients; interim analysis after 25th patient expected in H2 2026.
Patent already granted in US and Korea; pending in Europe, Canada, Brazil, China, and Israel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.